Literature DB >> 34490814

Autoimmune diseases of the brain, imaging and clinical review.

Ghazal Shadmani1, Tyrell J Simkins2, Reza Assadsangabi1, Michelle Apperson2, Lotfi Hacein-Bey1, Osama Raslan1, Vladimir Ivanovic1.   

Abstract

There is an extensive spectrum of autoimmune entities that can involve the central nervous system, which has expanded with the emergence of new imaging modalities and several clinicopathologic entities. Clinical presentation is usually non-specific, and imaging has a critical role in the workup of these diseases. Immune-mediated diseases of the brain are not common in daily practice for radiologists and, except for a few of them such as multiple sclerosis, there is a vague understanding about differentiating them from each other based on the radiological findings. In this review, we aim to provide a practical diagnostic approach based on the unique radiological findings for each disease. We hope our diagnostic approach will help radiologists expand their basic understanding of the discussed disease entities and narrow the differential diagnosis in specific clinical scenarios. An understanding of unique imaging features of these disorders, along with laboratory evaluation, may enable clinicians to decrease the need for tissue biopsy.

Entities:  

Keywords:  Central nervous system; autoimmune brain disease; brain; imaging

Mesh:

Year:  2021        PMID: 34490814      PMCID: PMC9130615          DOI: 10.1177/19714009211042879

Source DB:  PubMed          Journal:  Neuroradiol J        ISSN: 1971-4009


  132 in total

Review 1.  Neuroimaging of Multiple Sclerosis Mimics.

Authors:  Yathish Haralur; Laszlo L Mechtler
Journal:  Neurol Clin       Date:  2019-10-24       Impact factor: 3.806

2.  A nationwide survey of hypertrophic pachymeningitis in Japan.

Authors:  Tomomi Yonekawa; Hiroyuki Murai; Satoshi Utsuki; Takuya Matsushita; Katsuhisa Masaki; Noriko Isobe; Ryo Yamasaki; Mari Yoshida; Susumu Kusunoki; Kiyomi Sakata; Kiyotaka Fujii; Jun-ichi Kira
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-11-22       Impact factor: 10.154

3.  Management of paraneoplastic neurological syndromes: report of an EFNS Task Force.

Authors:  C A Vedeler; J C Antoine; B Giometto; F Graus; W Grisold; I K Hart; J Honnorat; P A E Sillevis Smitt; J J G M Verschuuren; R Voltz
Journal:  Eur J Neurol       Date:  2006-07       Impact factor: 6.089

4.  Putaminal involvement in Rasmussen encephalitis.

Authors:  Bhagavatheeswaran Rajesh; Chandrasekharan Kesavadas; Radhakrishnan Ashalatha; Bejoy Thomas
Journal:  Pediatr Radiol       Date:  2006-05-19

Review 5.  The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.

Authors:  Dimitrios Karussis
Journal:  J Autoimmun       Date:  2014-02-10       Impact factor: 7.094

6.  MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis.

Authors:  R Kurokawa; Y Ota; W Gonoi; A Hagiwara; M Kurokawa; H Mori; E Maeda; S Amemiya; Y Usui; N Sato; Y Nakata; T Moritani; O Abe
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-06       Impact factor: 3.825

7.  Comparison of 3D cube FLAIR with 2D FLAIR for multiple sclerosis imaging at 3 Tesla.

Authors:  M Patzig; M Burke; H Brückmann; G Fesl
Journal:  Rofo       Date:  2013-12-17

Review 8.  Pituitary autoimmunity: 30 years later.

Authors:  Patrizio Caturegli; Isabella Lupi; Melissa Landek-Salgado; Hiroaki Kimura; Noel R Rose
Journal:  Autoimmun Rev       Date:  2008-05-08       Impact factor: 9.754

9.  Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions.

Authors:  Niraj Mistry; Rasha Abdel-Fahim; Amal Samaraweera; Olivier Mougin; Emma Tallantyre; Christopher Tench; Tim Jaspan; Peter Morris; Paul S Morgan; Nikos Evangelou
Journal:  Mult Scler       Date:  2015-12-10       Impact factor: 6.312

Review 10.  The Diagnosis and Treatment of Autoimmune Encephalitis.

Authors:  Eric Lancaster
Journal:  J Clin Neurol       Date:  2016-01       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.